Clinical Trial Update: Comparative Study of Different Doses of Magnesium as a Protective Agent in Nephrotoxicity in Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 study comparing different doses of magnesium to prevent cisplatin-induced nephrotoxicity in cancer patients; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Magnesium sulfate (magnesium sulfate)

Snippet

Sponsor: Tanta University | Conditions: Cisplatin Adverse Reaction | Phase 2 | Status: COMPLETED